1. Home
  2. KSS vs CAPR Comparison

KSS vs CAPR Comparison

Compare KSS & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$14.91

Market Cap

1.6B

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

SELL

Current Price

$28.60

Market Cap

1.3B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
KSS
CAPR
Founded
1962
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.3B
IPO Year
1995
2011

Fundamental Metrics

Financial Performance
Metric
KSS
CAPR
Price
$14.91
$28.60
Analyst Decision
Sell
Strong Buy
Analyst Count
15
8
Target Price
$15.31
$44.63
AVG Volume (30 Days)
4.7M
970.6K
Earning Date
05-28-2026
05-12-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
N/A
EPS
2.38
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.21
$3.31
P/E Ratio
$5.95
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.09
$4.30
52 Week High
$25.22
$40.37

Technical Indicators

Market Signals
Indicator
KSS
CAPR
Relative Strength Index (RSI) 59.35 42.53
Support Level $13.91 $27.98
Resistance Level $16.82 $30.06
Average True Range (ATR) 0.77 1.41
MACD 0.31 -0.04
Stochastic Oscillator 74.28 35.27

Price Performance

Historical Comparison
KSS
CAPR

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: